Showing results (231-240 of 265) with videos related to
Sort By:
Pageof 27
Oncotarget|July 25, 2016
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4Chengyuan Xue, Denise M T Yu, Samuele Gherardi, et al.Organic & Biomolecular Chemistry|August 30, 2003
Syntheses and biological evaluation of vinblastine congenersMartin E Kuehne, William G Bornmann, Istvan Markó, et al.The International Journal of Biological Markers|April 18, 2013
Association of cytokines, high sensitive C-reactive protein, VEGF and beta-defensin-1 gene polymorphisms and their protein expressions with chronic periodontitis in the Chinese populationYe Tian, Jin-le Li, Liang Hao, et al.Journal of Proteomics|November 9, 2013
Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approachPatrick Y Kim, Owen Tan, Sonya M Diakiw, et al.Cell Reports|October 5, 2022
Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectoryXiaojun Yuan, Janith A Seneviratne, Shibei Du, et al.Cancer Research|April 4, 2018
Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCNChi Yan Ooi, Daniel R Carter, Bing Liu, et al.Cancer Medicine|November 6, 2024
Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastomaJanith A Seneviratne, Daenikka Ravindrarajah, Daniel R Carter, et al.The International Journal of Biological Markers|April 18, 2013
Comparative evaluation of cytokines in gingival crevicular fluid and saliva of patients with aggressive periodontitisYuan Yue, Qing Liu, Chunjiao Xu, et al.The International Journal of Biological Markers|July 22, 2014
Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of status of chronic inflammation and cancerYan-jun Wang, Ling He, Ming Yuan, et al.International Journal of Molecular Sciences|November 14, 2023
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven NeuroblastomaLei Zhai, Anushree Balachandran, Rebecca Larkin, et al.Pageof 27